- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04020861
Photobiomodulation Therapy and Transcutaneous Electrical Nerve Stimulation on Chronic Neck Pain Patients
September 3, 2021 updated by: Richard Eloin Liebano, Universidade Federal de Sao Carlos
This study evaluates the efficacy isolated and combinaded of photobiomodulation therapy with low level laser therapy and the transcutaneous electrical nerve stimulation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Non-specific chronic neck pain patients will be treated with low-level laser therapy and/or trancutaneous electricam nerve stimulation.
They will receive 10 sessions of treatment.
Before and after the treatment physical measures and psychosocial factors will be evaluted to verificy the efficay these electrophysical agents.
Study Type
Interventional
Enrollment (Actual)
144
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
SP
-
São Carlos, SP, Brazil, 13565-905
- Federal University São Carlos
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with non-specific chronic neck pain, defined as pain or discomfort in the posterior cervical region between the superior nuchal line and the first thoracic spinous process and / or shoulder girdle;
- Neck pain for at least 3 months;
- Neck Disability Index (NDI) score of 5 points or higher;
- Numeric Rating Scale (NRS) score of 3 or higher to pain intensity;
- Aged between 18 and 65 years;
- Men and women
Exclusion Criteria:
- Neck pain associated with nerve root compromise (measured by clinical examination of dermatomes, myotomes and reflexes);
- Previous spinal surgery;
- Patients treated with physical therapy for neck pain in the last 3 months previous the study;
- Severe spinal disorders such as fractures, tumors, inflammatory and infectious diseases;
- Any contraindication to low level laser therapy or transcutaneous electrical nerve stimulation;
- Rheumatic, metabolic, neurological or cardiopulmonary diseases;
- Patients who require artificial cardiac pacemakers;
- Skin diseases, mainly at the current application site;
- Tumors or cancer historic in the last 5 years;
- Pregnancy;
- If the patient started any physical activity in the last 2 weeks.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: FACTORIAL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: PBM + TENS
The patients will be submitted to the active PBM and active TENS
|
To active photobiomodulation therapy (PBMT) the patient will be oriented to lie preferably in prone.
The treatment area will be defined according to painful area.
In the active group will be used the followings parameters: low-level laser therapy, 808 nm, 4 infrared diodes, 180 mW, 9 J.
In the placebo PBMT will be performed a simulation of laser application.
The cluster probe will be positioned on painful area during the same time of active PBMT, the equipment will be turned on and set, however the trigger will be not actived and no beam will be applied.
To active transcutaneous electrical nerve stimulation (TENS) the patient will be oriented to lie preferably in prone.
Two or four electrodes standard square self-adhesive electrodes (5 × 5 cm2) will be positioned according to the painful area related by patient.
It will be used the following parameters: frequency of 100 Hz, pulse duration of 125 µs (positive phase), 30 minutes of current stimulation and the pulse amplitude will be increased until the patient reports a strong but comfortable paresthesia (including motor level stimulation but no painful TENS).
The amplitude will be adjusted (if necessary) each 5 minutes to keep a strong but comfortable paresthesia.
|
ACTIVE_COMPARATOR: PBM
The patients will be submitted to the active PBMT and placebo TENS
|
To active photobiomodulation therapy (PBMT) the patient will be oriented to lie preferably in prone.
The treatment area will be defined according to painful area.
In the active group will be used the followings parameters: low-level laser therapy, 808 nm, 4 infrared diodes, 180 mW, 9 J.
In the placebo PBMT will be performed a simulation of laser application.
The cluster probe will be positioned on painful area during the same time of active PBMT, the equipment will be turned on and set, however the trigger will be not actived and no beam will be applied.
To placebo transcutaneous electrical nerve stimulation (TENS) Two or four electrodes standard square self-adhesive electrodes (5 × 5 cm2) will be positioned according to the painful area related by patient.
This device was customized to deliver a current for 30 seconds (both channels) and then ramp off over the next 15 seconds so that it will be active for a total of 45 seconds.
This will permit the patient to fell the TENS sensation while applying the settings.
|
ACTIVE_COMPARATOR: TENS
The patients will be submitted to the placebo PBMT and active TENS
|
To active transcutaneous electrical nerve stimulation (TENS) the patient will be oriented to lie preferably in prone.
Two or four electrodes standard square self-adhesive electrodes (5 × 5 cm2) will be positioned according to the painful area related by patient.
It will be used the following parameters: frequency of 100 Hz, pulse duration of 125 µs (positive phase), 30 minutes of current stimulation and the pulse amplitude will be increased until the patient reports a strong but comfortable paresthesia (including motor level stimulation but no painful TENS).
The amplitude will be adjusted (if necessary) each 5 minutes to keep a strong but comfortable paresthesia.
In the placebo PBMT will be performed a simulation of laser application.
The cluster probe will be positioned on painful area during the same time of active PBMT, the equipment will be turned on and set, however the trigger will be not actived and no beam will be applied.
|
PLACEBO_COMPARATOR: Placebo
The patients will be submitted to the placebo PBMT and placebo TENS.
|
To placebo transcutaneous electrical nerve stimulation (TENS) Two or four electrodes standard square self-adhesive electrodes (5 × 5 cm2) will be positioned according to the painful area related by patient.
This device was customized to deliver a current for 30 seconds (both channels) and then ramp off over the next 15 seconds so that it will be active for a total of 45 seconds.
This will permit the patient to fell the TENS sensation while applying the settings.
In the placebo PBMT will be performed a simulation of laser application.
The cluster probe will be positioned on painful area during the same time of active PBMT, the equipment will be turned on and set, however the trigger will be not actived and no beam will be applied.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain intensity: Numerical Rating Scale (Pain NRS)
Time Frame: 2 weeks after randomization
|
Pain intensity will be evaluated using an 11-point (0-10) Numerical Rating Scale (Pain NRS), which is a simple and easy-to-use measuring scale that consists of a sequence of numbers from zero to 10, in which zero represents "no pain" and 10 represents "the worst pain imaginable".
The pain evaluation will be carried out verbally with the patient reporting the pain intensity.
|
2 weeks after randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain intensity: Numerical Rating Scale (Pain NRS)
Time Frame: 6 weeks after randomization
|
Pain intensity will be evaluated using an 11-point (0-10) Numerical Rating Scale (Pain NRS), which is a simple and easy-to-use measuring scale that consists of a sequence of numbers from zero to 10, in which zero represents "no pain" and 10 represents "the worst pain imaginable".
The pain evaluation will be carried out verbally with the patient reporting the pain intensity.
|
6 weeks after randomization
|
Pain intensity at movement: Numerical Rating Scale (Pain NRS)
Time Frame: 2 weeks after randomization
|
Pain intensity will be evaluated during the cervical movements of flexion, extension, right and left lateral inclination and right and left rotation, using an 11-point (0-10) Numerical Rating Scale (Pain NRS)
|
2 weeks after randomization
|
Neck disability
Time Frame: 2 weeks after randomization
|
Neck disability will be evaluated using neck disability index (NDI) that consists of a 10-item questionnaire that assess the impact of pain on daily activities using a score from 0 to 5 for each section, with higher values indicating more severe impact.
|
2 weeks after randomization
|
Cervical range of motion
Time Frame: 2 weeks after randomization
|
Cervical range of motion will be measured with a fleximeter
|
2 weeks after randomization
|
Pressure Pain Threshold
Time Frame: 2 weeks after randomization
|
Pressure pain threshold (PPT) in the neck, shoulder girdle and anterior tibialis muscle will be measured using a Somedic Type II pressure algometer
|
2 weeks after randomization
|
Pain temporal summation (TS)
Time Frame: 2 weeks after randomization
|
Temporal summation (TS) will be induced by a pressure algometer.
Ten (10) stimuli with a pressure of 40 kPa/s of the mean value of algometry performed prior on the upper trapezius.
Patients will be asked about their pain using NRS at the first, fifth and tenth stimulus.
|
2 weeks after randomization
|
Conditioned pain modulation (CPM)
Time Frame: 2 weeks after randomization
|
The conditioned stimulus for eliciting CPM will be the cold pressor test (Cold Water Bath test to the hand) and the test stimulus will be the assessment of PPT on the upper trapezius muscle.
|
2 weeks after randomization
|
Depressive symptoms
Time Frame: 2 weeks after randomization
|
The depressive symptoms will be performed using Beck Depression Inventory (BDI).
The scale consists of items including symptoms and attitudes whose intensity range from neutral to a maximum level of severity, rated from 0 to 3.
|
2 weeks after randomization
|
Pain catastrophizing
Time Frame: 2 weeks after randomization
|
Pain catastrophizing will be performed with Pain Catastrophizing Scale (PCS) - The PCS is a self-administered questionnaire that consists of 13 items to assess catastrophizers.
The items are rated on a 5-point Likert-type scale in which both intensity and frequency information are represented, with the following five levels of response for each Likert item: (0) not at all, (1) to a slight degree, (3) to a moderate degree, (4) to a great degree, (5) and all the time.
The total score is computed by summation of all items and the total score ranges from 0 to 52 points.
Higher scores indicate greater catastrophic pain.
|
2 weeks after randomization
|
Change in patient perception of quality of life:12-Item Short-Form Health Survey (SF-12)
Time Frame: 2 weeks after randomization
|
The quality of life will be performed using 12-Item Short-Form Health Survey (SF-12) version 2 questionnaire.
This is a self-report measure that assesses physical (Physical Component Summary - PCS) and mental (Mental Component Summary - MCS) health on a scale of 0 - 100.
Higher scores represent better levels of quality of life.
|
2 weeks after randomization
|
Analgesic intake
Time Frame: 2 weeks after randomization
|
Anlgesic intake will be evaluated asking to the patients all analgesic medications (opioids and non-opioids) taken one week prior to evaluation and during the treatment.
|
2 weeks after randomization
|
Global perceived effect (GPE)
Time Frame: 2 weeks and 6 weeks after randomization
|
Global perceived effect will be evaluated by an 11 - point (- 5 to + 5) Global Perceived Effect Scale.
It consists of an 11-point scale that ranges from -5 (vastly worse) through 0 (no change) to 5 (completely recovered).
|
2 weeks and 6 weeks after randomization
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 6, 2020
Primary Completion (ACTUAL)
June 25, 2021
Study Completion (ACTUAL)
July 25, 2021
Study Registration Dates
First Submitted
July 5, 2019
First Submitted That Met QC Criteria
July 12, 2019
First Posted (ACTUAL)
July 16, 2019
Study Record Updates
Last Update Posted (ACTUAL)
September 5, 2021
Last Update Submitted That Met QC Criteria
September 3, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAAE: 81711417.0.0000.5504
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The data will be available upon requested of principal investigator.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Neck Pain
-
The University of Hong KongActive, not recruitingChronic Low Back Pain | Chronic Neck PainHong Kong
-
Massachusetts General HospitalCompletedChronic Low Back Pain | Chronic Neck PainUnited States
-
Turku University HospitalCompletedChronic Low Back Pain | Chronic Neck Pain
-
Şenay ÖzdolapZonguldak Bulent Ecevit UniversityCompletedNeck Pain | Chronic Neck PainTurkey
-
KTO Karatay UniversityCompletedChronic Neck PainTurkey
-
Cairo UniversityCompletedChronic Mechanical Neck PainEgypt
-
Cairo UniversityCompletedChronic Non-Specific Neck PainEgypt
-
Beijing Sport UniversityCompletedChronic Non-specific Neck PainChina
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH); United States...CompletedChronic Low Back Pain | Chronic Neck PainUnited States
-
RANDUniversity of California, Los AngelesCompletedChronic Low Back Pain | Chronic Neck PainUnited States
Clinical Trials on Active PBM
-
University of FloridaNational Institute on Aging (NIA); University of ArizonaRecruitingCognitive Aging | Alzheimer Disease, Protection AgainstUnited States
-
LumiThera, Inc.National Eye Institute (NEI)CompletedAge Related Macular DegenerationCanada
-
University of MalagaCompletedChronic Pain | FibromyalgiaSpain
-
The University of Texas Health Science Center,...CompletedPostoperative PainUnited States
-
Seaborough Life Science B.V.University of Groningen; Chrono@Work B.V.Not yet recruitingSleep Deprivation | Circadian Rhythm Disorders
-
University of Nove de JulhoUnknownPhysical Therapy Modalities
-
PBM Healing International LimitedRecruitingMalocclusion | Orthodontic TreatmentCanada
-
Tufts UniversityNot yet recruitingSensation Disorders | Neuropathic Pain
-
PBM Healing International LimitedCompleted